The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence (AI). In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial intelligence in pharma: AI in multiomics. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
AI in multiomics is a key innovation area in artificial intelligence
AI-assisted multiomics involves using artificial intelligence and machine learning algorithms to integrate and analyze data from multiple omics sources, such as genomics, transcriptomics, proteomics, and metabolomics. The approach enables a comprehensive and personalized understanding of biological systems and disease mechanisms, leading to improved diagnosis, treatment, and drug discovery.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of AI in multiomics.
Key players in AI in multiomics – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to AI in multiomics
Source: GlobalData Patent Analytics
Molecular Health is one of the leading patent filers for AI in multiomics. Molecular Health is a leader in the hybridization of medicine, allowing healthcare professionals with software solutions in AI and data-driven technology for AI-guided drug development to deliver better patient outcomes.
In terms of application diversity, SureGene leads the pack, while Merck and PuraPharm stood in the second and third positions, respectively. By means of geographic reach, Expanse Bioinformatics held the top position, followed by Regeneron Pharmaceuticals and SureGene.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Artificial Intelligence (AI) in Healthcare.